# EDGAR Filing Document

**Accession Number:** 0000012208
**File Stem:** 0000012208-25-000047
**Filing Date:** 2025-7
**Character Count:** 12092
**Document Hash:** 5a43dab60e82eb5e9023cfd1ed6cbcc4
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000012208-25-000047.hdr.sgml**: 20250728

**ACCESSION NUMBER**: 0000012208-25-000047

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 15

**CONFORMED PERIOD OF REPORT**: 20250728

**ITEM INFORMATION**: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

**ITEM INFORMATION**: Other Events

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20250728

**DATE AS OF CHANGE**: 20250728

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** BIO-RAD LABORATORIES, INC.
- **CENTRAL INDEX KEY:** 0000012208
- **STANDARD INDUSTRIAL CLASSIFICATION:** LABORATORY ANALYTICAL INSTRUMENTS [3826]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 941381833
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-07928
- **FILM NUMBER:** 251155795

**BUSINESS ADDRESS:**
- **STREET 1:** 1000 ALFRED NOBEL DRIVE
- **CITY:** HERCULES
- **STATE:** CA
- **ZIP:** 94547
- **BUSINESS PHONE:** 5107247000

**MAIL ADDRESS:**
- **STREET 1:** 1000 ALFRED NOBEL DRIVE
- **CITY:** HERCULES
- **STATE:** CA
- **ZIP:** 94547

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** BIO RAD LABORATORIES INC
- **DATE OF NAME CHANGE:** 19920703

?xml version='1.0' encoding='ASCII'? bio-20250728

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K** 

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

**Date of Report: July 28, 2025** 

**(Date of earliest event reported)**

**BIO-RAD LABORATORIES, INC.** 

**(Exact name of registrant as specified in its charter)**

**Commission File Number: 1-07928** 

---

| | |
|:---|:---|
| **Delaware** | **94-1381833** |
| **(State or other jurisdiction of incorporation)** | **(I.R.S. Employer Identification No.)** |

---

**1000 Alfred Nobel Dr.**

**Hercules, California 94547** 

**(Address of principal executive offices, including zip code)**

**(510)724-7000** 

**(Registrant's telephone number, including area code)**

---

| | |
|:---|:---|
| Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: | Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: |
| ☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |

---

---

| | | |
|:---|:---|:---|
| Securities registered pursuant to Section 12(b) of the Act:  | Securities registered pursuant to Section 12(b) of the Act:  | Securities registered pursuant to Section 12(b) of the Act:  |
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
| Class A Common Stock, Par Value $0.0001 per share | BIO | New York Stock Exchange |
| Class B Common Stock, Par Value $0.0001 per share | BIO.B | New York Stock Exchange |

---

Indicate by check mark whether the registrant is an emerging growth company as deﬁned in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

---

| | | |
|:---|:---|:---|
| | Emerging growth company | ☐ |
| If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. | If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. | ☐ |

---

------

**ITEM 5.02&nbsp;&nbsp;&nbsp;&nbsp;Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.** 

As previously disclosed by Bio-Rad Laboratories, Inc. (the "Company") in its 2025 Definitive Proxy Statement on Schedule 14A filed with the U.S. Securities and Exchange Commission on March 26, 2025, Michael Crowley, the Company's Executive Vice President, Global Commercial Operations announced on January 31, 2025 that he plans to retire in 2025. On July 23, 2025, the Company's Board of Directors approved that effective as of the August 4, 2025 start date of his successor Rajat Mehta, Mr. Crowley will be retiring from this position and will no longer be an executive officer. He will continue as an employee until September 2025 to assist with the transition.

**ITEM 8.01. Other Events.**

On July 28, 2025, the Company issued a press release announcing the appointment of Rajat Mehta as Executive Vice President, Global Commercial Operations, effective August 4, 2025.

A copy of the press release announcing the appointment of Mr. Mehta and the retirement of Mr. Crowley is furnished with this report as Exhibit 99.1.

**ITEM 9.01&nbsp;&nbsp;&nbsp;&nbsp;Financial Statements and Exhibits**

---

| | |
|:---|:---|
| **Exhibit<br>Number** | **Description** |
| 99.1 | <u>[Press Release](bio-8k07282025xex991.htm)[of Bio-Rad Laboratories Inc.](bio-8k07282025xex991.htm)[dated](bio-8k07282025xex991.htm)[Ju](bio-8k07282025xex991.htm)[ly 28](bio-8k07282025xex991.htm)[, 20](bio-8k07282025xex991.htm)[25](bio-8k07282025xex991.htm)</u> |
| 104 | Cover Page Interactive Data File - the cover page XBRL tags are embedded within the Inline XBRL document |

---

------

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | | |
|:---|:---|:---|:---|
| | | **BIO-RAD LABORATORIES, INC.** | **BIO-RAD LABORATORIES, INC.** |
| Date: | July 28, 2025 | By: | /s/ Courtney C. Enloe |
|  |  |  | Courtney C. Enloe |
|  |  |  | EVP, General Counsel and Secretary |

---

## Exhibit 99.1

![image_0.jpg](image_0.jpg)

**<u>Exhibit 99.1</u>**

**Press Release**

**Bio-Rad Appoints Rajat Mehta Executive Vice President, Global Commercial Operations**

**HERCULES, Calif. – July 28, 2025** – Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced the appointment of Rajat Mehta as its new Executive Vice President, Global Commercial Operations, effective August 4, 2025. Mehta will lead Bio-Rad's global commercial strategy and execution, succeeding Mike Crowley, who is retiring after a distinguished 26-year career with the company.

Mehta brings extensive leadership and commercial expertise in biopharmaceutical, life science research, and diagnostics markets to Bio-Rad. He joins from Labcorp, where he served as Senior Vice President, overseeing large-scale commercial operations for the company's West Division. Prior to Labcorp, Mehta was Vice President and General Manager, Applied Technologies, at Thermo Fisher Scientific. In this role, he successfully managed a global business unit serving diverse markets. Earlier in his career, Mehta held commercial roles of increasing responsibility at Dow Chemical, where he designed and executed impactful commercial growth strategies. He holds an MBA from The Wharton School at the University of Pennsylvania and a BS in Electrical Engineering from Kurkshetra University in Thanesar, India.

"Rajat's proven track record in delivering above-market growth, building high-achieving teams, and driving alignment across multiple business segments will be instrumental as we continue to advance our long-term strategy," said Jon DiVincenzo, Bio-Rad's President and Chief Operating Officer. "His focus on commercial excellence and deep understanding of large, global organizations spanning both clinical diagnostics and life science markets make him a fantastic addition to our leadership team."

Norman Schwartz, Bio-Rad's Chairman and CEO, added, "On behalf of everyone at Bio-Rad, I want to extend our deepest gratitude and acknowledgement to Mike Crowley for his exceptional service and unwavering dedication. Since joining our commercial team in 1998, and particularly during his tenure as EVP of Global Commercial Operations since 2014, Mike's leadership has been instrumental in building our global sales and services organization and contributing to Bio-Rad's overall success."

------

**About Bio-Rad**

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B) is a leader in developing, manufacturing, and marketing a broad range of products for the life science research and clinical diagnostics markets. Based in Hercules, California, Bio-Rad operates a global network of research, development, manufacturing, and sales operations with approximately 7,500 employees, and $2.6 billion in revenues in 2024. Our customers include universities, research institutions, hospitals, and biopharmaceutical companies, as well as clinical, food safety and environmental quality laboratories. Together, we develop innovative, high-quality products that advance science and save lives. To learn more, visit bio-rad.com.

**Forward-Looking Statements** 

*This release may be deemed to contain certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, without limitation, statements we make regarding our executive officers. Forward-looking statements generally can be identified by the use of forward-looking terminology such as "plan", "believe," "expect," "anticipate," "may," "will," "intend," "estimate," "continue," or similar expressions or the negative of those terms or expressions, although not all forward-looking statements contain these words. Such statements involve risks and uncertainties, which could cause actual results to vary materially from those expressed in or indicated by the forward-looking statements. These risks and uncertainties include risks relating to our international operations; global economic and geopolitical conditions; tariffs or other trade barriers; reductions in government funding or capital spending of our customers; the uncertain pace of the biopharma sector's recovery; international legal and regulatory risks; our ability to develop and market new or improved products; our ability to compete effectively; foreign currency exchange fluctuations; supply chain issues; product quality and liability issues; our ability to integrate acquired companies, products or technologies into our company successfully; changes in the healthcare industry; and natural disasters and other catastrophic events beyond our control. For further information regarding our risks and uncertainties, please refer to the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operation" in Bio-Rad's public reports filed with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K and our Quarterly Reports on Form 10-Q. Bio-Rad cautions you not to place undue reliance on forward-looking statements, which reflect an analysis only and speak only as of the date hereof. We disclaim any obligation to update these forward-looking statements.*

**Investor Contact:**<br>Edward Chung, Investor Relations<br>510-741-6104<br><u>ir@bio-rad.com</u>

**Media Contact:**<br>Anna Gralinska, Corporate Communications<br>510-741-6643<br><u>cc@bio-rad.com</u>

<br>